# NCT02762006 (NCT02762006)

> Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: durvalumab plus tremelimumab
- Indication: locally advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02762006
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Moshe Ornstein
- Conditions: Renal Cell Carcinoma; Kidney Cancer
- Interventions: Durvalumab; Tremelimumab
- Enrollment: 29
- Primary outcome: Patients with Dose Limiting Toxicity (DTL)

## Indexed commentary on NCT02762006 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02762006